The Cochrane Schizophrenia Group

Standardisation in Mental Health: Social and Ethical Dimensions

Attachments:  Pickersgill_2011    Martyn Pickersgill

Date:  May 1st 2013
Time:  5.30pm (followed by light refreshments)
Venue:   B63 Law and Social Sciences Building, University Park, The University of Nottingham Read the rest of this entry »

Advertisements
Leave a comment »

Making Sense of Voices – Maastricht Interview Training

One and Other-Mental Health

One and Other-Mental Health (Photo credit: Feggy Art)

Attachments: Maastricht Flyer       Booking Form Maastricht2013

Venues 1:  The Crown Hotel, Crown Place  Harrogate, HG1 2RZ
Date:  3rd, 4th and 5th July 2013

Venue 2:  The Institute of Mental Health Building , Innovation Park, Triumph Road, Nottingham NG7 2TU
Date:  17th, 18th and 19th September   2013

Venue 3:  Wirral Mind, 90-92 Chester Street, Birkenhead CH 41 5DL
Date:  15th, 16th and 17th October 2013 Read the rest of this entry »

Leave a comment »

Processing the process: Systematic Reviews

By Angelique Bodart, Editorial Assistant for the CSzG

As you look through the Cochrane Library > Schizophrenia and Psychosis you notice that the one thing you were hoping to find isn’t there but you know for a fact that there’s trials out there looking at that exact thing.  Why is there not a systematic review on that topic?  Because you or another clinician have not contacted us to ask to write one, or perhaps it is being done behind the scenes you just don’t know it yet.  As we have seen from Prescribing as a junior doctor: do we know what we think we know? and The Clozapine rollercoaster, systematic reviews are very important to doctors, they are also very important to patients, as they enable both to make an informed decision about how to treat schizophrenia or at least support recovery and stability.  Unfortunately systematic reviews of drugs, therapies, ECT, hospitalisation procedures etc. don’t happen by magic.  They happen because someone has contacted us with an interest they wish to pursue, to establish the usefulness of, with other like-minded people. Read the rest of this entry »

1 Comment »

The Clozapine rollercoaster

By Mahesh Jayaram, CSzG Editor and Clinical Consultant Psychiatrist

This is my first ever blog, hence not sure how I go about writing this, however here it goes….
My life as a psychiatrist often involves dealing with people who present with difficulties that even after years of knowing someone takes me aback. Not knowing what challenge will present itself is what makes my job interesting keeps me going. Sometimes though, there is the frustration of coming across the same problem that has confronted me before and not having the right solutions. Patients suffering from schizophrenia have to deal with not only their symptoms, which can often be intrusive and disabling but also with the consequences of suffering from the illness, stigma and impact, it has on their lives. In addition, the medications that are available for this condition are imperfect and cause unacceptable side effects. Read the rest of this entry »

1 Comment »

Prescribing as a junior doctor: do we know what we think we know?

Generic

Generic (Photo credit: Kraemer Family Library)

By Jennifer Nelson, Junior Doctor

“Evidence-based medicine” (EBM) is a term that is familiar to all junior doctors. But how often do we really consider EBM in our everyday practice? Are our decisions on how to treat patients made after careful consideration of the evidence, or do we simply follow trust protocols, or, more likely, go with a sort of “gut-feeling” about which treatment to offer?

Recently,  I was asked to review a patient with paranoid schizophrenia who is currently relapsing. He had been restarted on the antipsychotic Aripiprazole two weeks prior to me seeing him. He was starting to show signs of improvement; the voices were diminishing and he was gaining partial insight into the fact that the “pills” might be helping him. At the end of the interview, I decided to suggest an increase in the dose of Aripiprazole from 15mg to 20mg.  Read the rest of this entry »

2 Comments »